Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
7.84
0.00 (-0.06%)
Feb 11, 2026, 4:00 PM EST - Market closed
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$541,818
Profits / Employee
-$1,129,604
Market Cap
681.78M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 579 |
| Replimune Group | 479 |
| Rigel Pharmaceuticals | 164 |
| Alpha Tau Medical | 125 |
| Cullinan Therapeutics | 111 |
| enGene Holdings | 82 |
| Fulcrum Therapeutics | 45 |
| Bright Minds Biosciences | 26 |
KURA News
- 5 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy - Seeking Alpha
- 4 weeks ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 2 months ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha
- 2 months ago - Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - GlobeNewsWire
- 2 months ago - Kura Oncology: A Cautious Buy - Seeking Alpha
- 2 months ago - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data - Seeking Alpha